Biocon gets US FDA VAI status for Cranbury facility

Regulatory & Legal View source PDF Explain this filing

BIOCON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.6%Reaction day

₹391.50

prior close

₹394.90

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+1.2%+0.5% vs market

Pharmaceuticals peers, median of 153sector+0.6%+1.0% vs sector

On the reaction day the stock moved 0.5 pts more than Nifty Midcap 150 and 1.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.8

10m

+0.9

15m

+0.8

30m

+1.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.6+1.2+0.5+0.6+1.0

Next day

+1.9+2.0-0.1+1.3+0.6

+2.4+2.1+0.3+1.4+1.0

+1.7+1.6+0.1+1.4+0.3

+1.0+1.4-0.3+0.7+0.3

-0.2+1.0-1.1+0.0-0.2

+0.5+1.8-1.3+0.7-0.2

15d

-5.3+0.3-5.5-1.0-4.2

-4.2-0.1-4.1-1.8-2.4

-2.7-0.4-2.4-4.0+1.3

-5.7-8.1+2.4-10.2+4.4

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 153Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Biocon received an Establishment Inspection Report with Voluntary Action Indicated (VAI) status from the US FDA for its Biocon Generics Inc facility in Cranbury, New Jersey, after a cGMP inspection conducted from October 6 to 10, 2025. VAI is a favorable classification meaning no mandatory regulatory action is required.

Likely market impact

Positive outcome - no regulatory action needed, supports uninterrupted US operations and may boost investor confidence.